Drug Details
| General Information of the Drug (ID: DR4517) | ||||
|---|---|---|---|---|
| Name |
Tetramethylpyrazine
|
|||
| Synonyms |
2,3,5,6-Tetramethylpyrazine; TETRAMETHYLPYRAZINE; 1124-11-4; Ligustrazine; Pyrazine, tetramethyl-; Bs factor; Tetramethylpyrazin; Tetrapyrazine; Chuanxiongzine; Liqustrazine; Ligustizine; 2,3,5,6-Tetramethyl pyrazine; TMPZ; chuanxingzine; FEMA No. 3237; UNII-V80F4IA5XG; MFCD00006146; 2,3,5,6,-Tetramethyl-1,4-pyrazine; V80F4IA5XG; MLS000069594; FEMA 3237; Pyrazine, 2,3,5,6-tetramethyl-; SMR000059042; 2,5,6-Tetramethylpyrazine; EINECS 214-391-2; NSC 36080; NSC 46451; 2,3,5,6-Tetramethylpyrazine (natural); Ligustrazin; PubChem8617; Opera_ID_849; TMP?; ACMC-2099er; DSSTox_CID_27070; DSSTox_RID_82085; DSSTox_GSID_47070; SCHEMBL77624; CHEMBL303697; ZINC4042; 2,3,5,6-Tetramethyl-pyrazine; DTXSID6047070; FINHMKGKINIASC-UHFFFAOYSA-; CHEBI:133246; Pyrazine, 2,3,5,6-tetramethyl; HMS2235K03; HMS3371J08; Nat.2,3,5,6-Tetramethylpyrazine; ACN-S003305; HY-N0264; NSC36080; NSC46451; Tox21_302313; ANW-16465; BBL012277; CT0189; NSC-36080; NSC-46451; s3956; SBB085945; STL163591; 2,3,5,6-Tetramethylpyrazine, 98%; AKOS003398567; CCG-207974; CS-W023183; MCULE-2834033564; NCGC00247063-01; NCGC00256097-01; AC-10515; AK-47432; AS-13206; H601; SY011353; CAS-1124-11-4; DB-003786; AM20070299; FT-0609443; N1918; ST45025457; 2,3,5,6-Tetramethylpyrazine, >=98%, FG; M-4966; 2,3,5,6-Tetramethylpyrazine, analytical standard; A802574; AC-907/25014219; Q-100069; 2,3,5,6-Tetramethylpyrazine, natural, >=98%, FG; Q11319317; Z1741976694; 2,3,5,6-Tetramethylpyrazine, Vetec(TM) reagent grade, 98%
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Dissociative neurological symptom disorder [ICD-11: 6B60] | Discontinued in Phase 2 | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C8H12N2
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC1=C(N=C(C(=N1)C)C)C
|
|||
| InChI |
1S/C8H12N2/c1-5-6(2)10-8(4)7(3)9-5/h1-4H3
|
|||
| InChIKey |
FINHMKGKINIASC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1124-11-4
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Artesunate | Artemisia annua | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BDNF | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | GFAP | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ICAM1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | NGF | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | NTF3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VCAM1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | For a xenograft model, 1 * 106 parasitized red blood cells (pRBCs) were injectedinto C57BL/6 mice via intraperitoneal (i.p.). | |||||
| Experimental
Result(s) |
The neuroprotective effects of artesunate + tetramethylpyrazine were mainly related to proteins involved in axon development and transportation between blood and brain. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Preproendothelin-1 (EDN1) | Molecule Info | [3] | |
